EXACT Sciences Corporation

EXACT Sciences — Technical Presentation (October 2010)

29 slides from EXACT Sciences's technical presentation, Oct 28, 2010

  1. Slide 1: Presentation of Validation Study Results

    Presentation of Validation Study Results October 28, 2010

  2. Slide 2: Safe Harbor Statement

    Certain matters contained in this presentation, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to, among other things, our expectations concerning the timing of pote

  3. Slide 3: Agenda

    Agenda 2 News and Background About the Test About the Study Study Results Next Steps News and Background About the Test About the Study Study Results Next Steps

  4. Slide 4: Validation Study Overview

    Validation Study Overview 3 Overall purpose of study was to validate the company’s colorectal cancer and pre-cancer screening test panel The study was a part of an overall process of technology development and marker selection Validation study included a specificity study, followed by training and t

  5. Slide 5: Summary of Validation Study Results

    Summary of Validation Study Results 4 85% sensitivity cancer 64% sensitivity pre-cancer (>1cm) Combined Training & Test Sets 88% specificity News and Background About the Test About the Study Study Results Next Steps

  6. Slide 6: Clinical Significance of Study Results

    Clinical Significance of Study Results Cologuard™ assay has real potential as a colorectal cancer screening tool No non-invasive product exists that can detect 60% of pre-cancerous polyps Test may assist gastroenterologists in finding more pre-cancerous polyps and colorectal cancers Simple, affordab

  7. Slide 7: Non-Invasive Colorectal Cancer Detection is Difficult

    Non-Invasive Colorectal Cancer Detection is Difficult Long road to positive results Marker challenges: methylation markers are key Technology challenges: most detection methods won’t work reliably QuARTS™ technology is a big deal Challenging DNA extraction from stool Other non-invasive (fecal blood

  8. Slide 8: The Exact Sciences' Solution: Distinct Pathways

    The Exact Sciences’ Solution: 3 Distinct Pathways DNA methylation markers DNA mutation markers Hemoglobin marker Single Test Result If positive, refer to colonoscopy + + News and Background About the Test About the Study Study Results Next Steps 7

  9. Slide 9: Methodical Product Development Approach

    Methodical Product Development Approach 8 Sequencing Study Tissue Study Pilot Study Specificity Study Training Set Test Set 32 methyl. Markers Narrowed markers to 9 Unpublished data Generated IP on methylation markers 9 markers With 4-marker subset, 100% of cancers and pre-cancers detected at 100% s

  10. Slide 10: Validation Study Overview

    Validation Study Overview 9 Goal of study was to validate technology, marker selection and evaluate clinical performance prior to beginning pivotal clinical trial 1,178 stool samples processed and analyzed Study conducted at Exact Sciences and Mayo Clinic All training and test set samples were blind

  11. Slide 11: Validation Study Samples

    Validation Study Samples 10 Tough samples to find: Exact had access to rare samples Five different collection & storage protocols Samples collected and stored at -80°C over last 7 years Varying stool processing protocols by site Preservative-to-stool dilution ratio varied from ~8:1 to 4:1 Sample pro

  12. Slide 12: Overall Study Results

    Overall Study Results 11 85% sensitivity cancer 64% sensitivity pre-cancer Overall Study Results 88% specificity News and Background About the Test About the Study Study Results Next Steps

  13. Slide 13: Pilot Study Results

    Submitted data to AACR on August 23, 2010 Pilot Study 12 85% sensitivity cancer 55% sensitivity pre-cancer Pilot Study Results: with 3 markers 90% specificity News and Background About the Test About the Study Study Results Next Steps Test 118 samples 59 normal 29 adv adenomas 30 cancers

  14. Slide 14: Specificity Study

    Specificity Study Tested 500 samples to determine biases introduced by: Age Gender Ethnicity Geography Learned only age-related methylation bias occurs Developed age-related logistic regression Data assisted in setting methylation marker cutoffs 13 News and Background About the Test About the Study

  15. Slide 15: Training Set Results

    Establish cutoff Training Set Results 14 89% sensitivity cancer 64% sensitivity pre-cancer Training Set Results 89% specificity News and Background About the Test About the Study Study Results Next Steps

  16. Slide 16: Test Set Results

    Independently assess test performance Test Set Results 15 78% sensitivity cancer 64% sensitivity pre-cancer Test Set Results 85% specificity News and Background About the Test About the Study Study Results Next Steps

  17. Slide 17: Sensitivity by Cancer Stage

    Sensitivity by Cancer Stage 16 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Cancer Stage

  18. Slide 18: Sensitivity by Adenoma Size

    Sensitivity by Adenoma Size 17 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Adenoma Size (cm)

  19. Slide 19: Sensitivity by Lesion Site

    Sensitivity by Lesion Site 18 News and Background About the Test About the Study Study Results Next Steps Sensitivity (%) Proximal (Right) Distal (Left) Cancer Pre-Cancer

  20. Slide 20: Overview of Validation Study Samples

    Overview of Validation Study Samples 19 Table 1: Participant and Lesion Characteristics

  21. Slide 21: Technical Significance of Study Results

    Technical Significance of Study Results First non-invasive test to detect > 50% of pre-cancerous polyps and 85% of cancers with high specificity Demonstration of QuARTS™ technology as a superior method to detect both methylation and mutation markers Selection and validation of a multi-marker panel S

  22. Slide 22: Clinical Significance of Study Results

    Clinical Significance of Study Results Cologuard™ assay has real potential as a colorectal cancer screening tool No non-invasive product exists that can detect 60% of pre-cancerous polyps Test may assist gastroenterologists in finding more pre-cancerous polyps and colorectal cancers Simple, affordab

  23. Slide 23: What Can Be Improved?

    What Can Be Improved? Product Sample Study QC processes and assay reproducibility Improve DNA capture efficiency Improve mutation assays Improve hemoglobin detection Optimize multiplex methylation assays Single collection device Consistent buffer-to-stool dilution ratio Consistent stool processing p

  24. Slide 24: Exact Sciences' Next Steps

    Exact Sciences’ Next Steps 23 DNA extraction Detection assay Finalize collection kit GMP manufactured product Validated reagents News and Background About the Test About the Study Study Results Next Steps Work with FDA and CMS to finalize Narrow list of agencies’ questions Enroll sites Side studies

  25. Slide 25: Conclusions

    Conclusions Tremendous results in achieving targets Strong pre-cancer detection Identified areas to improve product and clinical trial design Potential to improve clinical outcomes Achieved goals of validating assay, technology and markers 24 News and Background About the Test About the Study Study

  26. Slide 26: Acknowledgements

    Thank you to the Mayo Clinic and Exact Sciences employees. Thanks also to Dr. Bert Vogelstein, Dr. Sandy Markowitz, Rob Cascella and Stan Lapidus. This company’s progress would not be possible without them.

  27. Slide 27: Questions & Answers

    Questions & Answers eG exact

  28. Slide 28: Appendix

    Appendix eG exact

  29. Slide 29: The Colon Cancer Epidemic

    The Colon Cancer Epidemic 28 150,000 new cases in U.S. 50,000 deaths in U.S. 600,000 deaths worldwide Source: ACS: Cancer Facts and Figures 2008 Ovary Prostate Pancreas Breast Colorectal Lung Cervix 15,520 28,660 34,290 40,930 49,960 159,390 3,870 U.S. Annual Cancer Mortality

Exact Sciences — Technical Presentation (October 2010) on 6ix